fbpx Skip to main content

Coronavirus Member Resources

A message from Biocom’s CEO:

Thank you to the thousands of California life science companies for your extraordinary work to diagnose, treat, and prevent COVID-19.  There has been, and will continue to be, an aggressive effort to mitigate the impact of the coronavirus, led by researchers, technicians, scientists and others in the life science community.

As the country takes important steps to ensure the health and welfare of the world’s citizens, we are grateful to the local, state, and federal officials who recognize the importance of the life science industry to combat the coronavirus.  This builds on the support for all of our life science companies working to develop therapeutics and products to improve human health across the disease spectrum.   Thank you especially to our California officials for supporting us and recognizing our need to remain open every day.

We are grateful to be recognized as important and essential players in this time of great need.

– Joe Panetta

  • Chan Zuckerberg Biohub COVID-19 testing lab:  Reagents (Zymo, ThermoFisher), Zymo kits, instruments, tips. Please see this spreadsheet for a detailed list of requests and contact information.  If you have questions, contact Merlin Lange.
  • Innovative Genomics Institute (IGI) COVID-19 testing lab: Instruments, scientist volunteers willing to become CLIA-trained.  Visit this IGI website for details.
  • UCSF Hospitals: Seeking PPE donations
    • UCSF Mount Zion Medical Center
      1600 Divisadero St., San Francisco
      Semicircle driveway
    • UCSF Mission Center Building
      1855 Folsom St., San Francisco
      Entrance in the parking lot on Harrison at 15th Street
    • UCSF Benioff Children’s Hospital Oakland
      747 52nd St., Oakland
      Ambassador Desk
    • The donation sites will accept the following supplies:
      • Unused N95 respirators and surgical masks. They can be opened, as long as they have not been used.
      • Unopened packages of disposable gloves
      • Unopened containers of hand sanitizer
      • Unopened containers of disinfectants and disinfecting wipes
      • Packaged, unused protective goggles.
      • Please note: We cannot accept any other supplies at this time and must keep storage space at our donation sites available for the items above.
    • Employee Volunteers There is an urgent need for available UCSF faculty and staff to be redeployed to fill the staffing needs in UCSF Health. Please consult with your direct supervisor before signing up for roles/shifts outside of your department. To sign up, visit the COVID Workforce Platform
  • San Mateo County public health department testing labs:  Nitrile gloves, fluid resistant gowns, N95 masks, surgical masks, heavy duty isolation gown, surgical gowns.  If you have stock to donate or sell, please email:  SMCMedDonations@smcgov.org
  • South San Francisco Fire are in need of N95 masks. Please contact: Richard.Walls@ssf.net
  • Stanford Clinical Lab – COVID-19 Testing Needs:   RNA extraction kits (unopened), Instruments.  Visit this site for details on items needed and how to donate.  https://yehlab.stanford.edu/stanford-covid
  • Stanford Health Care & Stanford Children’s Hospital: In need of personal protective equipment, in particular of N95 & surgical masks. They are accepting all donations of N95 masks, face shields, bunny suits & surgical masks, as long as they are in unopened boxes, in the manufacture’s original packaging. View Donation Guidelines or email covid19supplies@stanfordhealthcare.org to directly contact Stanford Medical Supply Chain.
  • Stanford Hospital
    • PPE Needed: 3M N95 1860 mask (standard), 3M N95 1860s mask (small), 3M N95 1870+ mask (large), O&M Halyard 46727, O&M Halyard 46767, O&M Halyard 46867, Cardinal Health USA-N95-S, Cardinal Health USA-N95-R, Cardinal Health 9500-N95S, Cardinal Health 9500-N95, Industrial N95s (3M 8210e NIOSH-Certified providing a filtration efficiency of at least 95%), FFP2 (Non-medical N95) and FFP3 (Non-medical N99).
    • Please note that surgical masks must meet the following requirements: Mask must have a 98% bacterial filtration efficiency, sub-micron particulates filtration efficient at 0.1 micron, & be fluid resistant (resistance to penetration by synthetic blood, minimum pressure must pass results of: 160mm Hg).
    • CONTACT: Brooke Howitt at bhowitt@stanford.edu.

Statewide

Bay Area

San Diego

Los Angeles

Orange County

Updates on possible disruptions to the daily and future operations, travel and supply chains of our California life science members.

Supply Chain:

Travel & Workplace:

Laboratory

Environmental Health & Safety

Check back often for Biocom workshops and events that address evolving COVID-19 concerns, as well as any updates or possible cancelations of larger events and conferences. View our updated events policy here.

Regulatory Rundown: Week of March 9-13, 2020

Learn about key regulatory takeaways from this week’s coronavirus news and developments.

READ MORE

Coronavirus Roundtable: HHSA Response and Company Prevention Measures

How is your company preparing for and responding to the novel coronavirus (COVID-19)? Read takeaways from Biocom’s March 6th event that brought together industry Environmental Health & Safety managers from companies of all sizes in San Diego to discuss just that.

READ SUMMARY

Biocom Japan Updates:

  • Telecommuting and virtual meetings: As of March 1, 46% of companies in Japan are to some extent telecommuting or conducting meetings online. Many large companies will continue to telecommute through mid-March and reassess at that time.
  • Events: Many events are getting cancelled, including BioAsia (3/10-3/11), while some others being postponed. BioJapan, scheduled for October, is still taking place at this time. Members should remain in close contact with event organizers.

Biocom is proud of the swift actions of our member companies and the work they are doing to address COVID-19.

Abbott

Abbvie

  • Doctors in China have started using a combination of AbbVie Inc.’s HIV drugs ritonavir and lopinavir at hospitals. A clinical trial is assessing whether the combination, sold under the brand name Kaletra, is more effective than an antiviral medicine known as interferon-alpha 2b in treating patients.
  • Read More – Bloomberg

AccendoWave

  • COVID-19 Infection Control Solution for Hospitals; Hospital Grade Cell Phone UV Sanitizing and Charging Carts to Hospital ED’s, L&D, and ICU’s.

Aragen

  • Aragen is producing reagents that are incorporated into COVID-19 test kits. 

Arcturus Therapeutics

Augmenta Bioworks

  • Working on treatments for COVID-19.

Berkeley Lights

Chan Zuckerberg

Distributed Bio

  • Coronavirus spreads faster than influenza, scientist from Netflix’s ‘Pandemic’ says
  • Read More – Fox

Drug Delivery Experts

  • Maintaining laboratory operations for some critical pharmaceutical drug development programs for client projects.
  • Donating PPE for clinical use (gloves, masks, gowns).
  • Continuing the work to complete a sterile fill finish suite (available July 2020) so that we can serve as one of the 4 or 5 GMP suites for injectable clinical supplies and GLP preclinical supplies in the San Diego area.

Eli Lilly

Genentech

Gilead

  • Assisting in development and testing of therapies (trial).
  • Working with Chinese health authorities to set up a randomized clinical trial in the country of its experimental antiviral drug remdesivir (used for Ebola), which has shown some potential in animal studies against the related coronaviruses MERS and SARS.
  • Bring deep experience in antiviral research and development and the global reach that many of the dozen or so biotechs working on coronavirus therapeutics lack. Has drawn attention for the potential of its antiviral drug remdesivir (now are accelerating lab testing of this drug to see its affects against coronavirus).
  • Read More – BioPharma Dive
  • Read More – The Economist

GSK

  • Assisting in development and testing of therapies.
  • One of the world’s largest producers of vaccines, has made its vaccine adjuvant technology (makes vaccines more effective & boosts immunity) available to companies and universities partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) on coronavirus vaccine development.
  • Brings deep experience in antiviral research and development and the global reach that many of the dozen or so biotechs working on coronavirus therapeutics lack.
  • In theory, the adjuvant should cut the amount of antigen that is needed to create effective vaccines. That benefit, known as antigen sparing, is particularly sought after during pandemic outbreaks as it enables more people to be vaccinated using available antigen supplies.
  • Coalition for Epidemic Preparedness Innovations (backed by Bill & Melinda Gates Foundation).
  • Australia’s University of Queensland is the first CEPI-partnered group to formalize an agreement with GSK, which will supply its AS03 adjuvant system to the university.
  • Read More – Fierce Biotech

Hologic

IndieBio

Inovio Pharmaceuticals

  • The Coalition for Epidemic Preparedness Innovations signed contracts with drugmakers including Moderna and Inovio Pharmaceuticals Inc. as early as Jan. 22 to expedite work.
  • Read More – Bloomberg

Ligand Pharmaceuticals

  • Using technology to boost drug solubility as part of Gilead’s antiviral drug remdesivir that’s undergoing testing for COVID-19
  • Read More

Lucidant

  • Lucidant Polymers is a specialty polymers manufacturer which directly supplying materials for RNA and DNA sequencing.  Data derived from that is key to understanding the spread of coronavirus, its mutation rates and should provide vital clues on the efficiency of any potential vaccine.

Mammoth Biosciences

  • Given the global health emergency, rapid transmission, and severe respiratory disease associated with the outbreak of the 2019 novel coronavirus (SARS-CoV-2), Mammoth Biosciences has reconfigured our ​DETECTR platform to rapidly and accurately detect SARS-CoV-2 using a visual lateral flow strip format within 30 minutes from sample to result.
  • Read More – Mammoth Biosciences

Marsh

McDermott Will & Emery

Pfizer

Procopio

Quidel Corp.

Roche

San Diego Blood Bank

Scripps Research

Sorrento Therapeutics and Celularity

  • Both companies have initiated a clinical and manufacturing collaboration to expand therapeutic use of existing cell therapy.
  • Companies have a longstanding relationship and both have expressed interest in starting clinical development efforts for anti-coronavirus allogeneic NK cell therapy immediately.
  • Looking to expand use of Celularity’s CYNK-001, an allogeneic, off-the-shelf, placental-derived Natural Killer (NK) cell therapy, to the treatment and prevention of coronavirus infections.
  • Sorrento would utilize current existing capacity in its “state-of-the-art” cGMP cell therapy manufacturing facilities in San Diego to supplement Celularity’s new cGMP facility in Florham Park, New Jersey. The combined capacity would support the rapid scale-up and sustained production of the novel cell therapy.
  • Sorrento in contact with leading scientists and local Chinese experts to discuss clinical validation and logistics requirements to fast-track CYNK-001 cell therapy available in China for this particularly urgent indication.
  • Read More – BioSpace

SynBioBeta

ThermoFisher Scientific

  • Providing genetic analysis solutions for coronavirus 2019-nCoV.
  • Thermo Fisher Scientific is an industry-leading, worldwide, trusted partner with comprehensive, end-to-end solutions for pathogen detection; scientific expertise; and the support capabilities critical to combating the current outbreak.
  • Utilizes Applied Biosystems TaqMan Assay technology to provide specific, sensitive, and accurate results.
  • Read More – ThermoFisher
  • Thermo Fisher to produce millions of coronavirus diagnostic tests

Twist Biosciences (working with Inovio)

UCSD

  • Evaluating a new diagnostic testing system designed by Fluxergy that could dramatically reduce wait times for COVID-19 testing in patients
  • Read More

Veolia

Vir Biotechnology

  • Vir Biotechnology Announces Research Collaboration with the National Institutes of Health Vaccine Research Center on Antibodies Against Coronaviruses
  • Read More

See also: Coronavirus Drug Update: The Latest Info On Pharmaceutical Treatments And Vaccines

Biocom takes a global approach in all that we do. As a representative of over 1,300 organizations connected to California’s life science industry, we strive to provide information that could benefit this community and their pursuit of innovation. The above resources are not to be taken as medical advice but as a means to stay informed and updated.